Neuraxis (NRXS) Stock: Buy, Sell, or Hold?
NRXS - Neuraxis, Inc.
$5.74
0.05 (0.88%)
▲
5d:
-5.44%
30d:
-8.45%
90d:
-16.69%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When NRXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NRXS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NRXS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NRXS is currently trading at $5.74, which is considered oversold relative to its 30-day fair value range of $5.83 to $6.55.
Technical Outlook: Technically, NRXS is in a strong downtrend. The price is currently testing key support at $5.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRXS scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+91.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NRXS is in a strong downtrend. The price is currently testing key support at $5.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRXS scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+91.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.83 -
$6.55
Company Quality Score
43/100
(HOLD)
Options IV Signal
40th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 40th percentile)
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 91.6% below Wall St target ($11.00)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.83 -
$6.55
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.61
(10.6%)
Support & Resistance Levels
Support Level
$5.57
Resistance Level
$6.12
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.26
Wall Street Target
$11.00
(+91.6%)
Revenue Growth (YoY)
115.7%
Profit Margin
-144.4%
Share & Embed Analysis
Last updated: September 13, 2026 2:24 PM ET
Data refreshes hourly during market hours. Next update: 3:24 PM
Data refreshes hourly during market hours. Next update: 3:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRXS showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian Allen Carrico
BUY
8060 shares
2026-04-01
Thomas Joeseph Carrico
BUY
667 shares
2026-04-01
Timothy Robert Henrichs
BUY
7593 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
